Norges Bank
NVLN

Norges Bank’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Norges Bank’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-39,700
Closed -$146K – 2182
2018
Q2 		$146K Hold
39,700
– – ﹤0.01% 2113
2018
Q1 		$139K Hold
39,700
– – ﹤0.01% 2119
2017
Q4 		$124K Hold
39,700
– – ﹤0.01% 2109
2017
Q3 		$279K Hold
39,700
– – ﹤0.01% 2113
2017
Q2 		$366K Sell
39,700
-6,496
-14% -$62.6K ﹤0.01% 2096
2017
Q1 		$495K Sell
46,196
-24,739
-35% -$253K ﹤0.01% 2105
2016
Q4 		$594K Buy
+70,935
New +$628K ﹤0.01% 2108

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Norges Bank's NVLN Position: Q3 2018 in Review

Norges Bank sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2018, closing a stake of 39,700 shares — an estimated $146K sold.

Norges Bank first reported a position in NVLN in Q4 2016 and held it in 7 quarters. The position peaked at $594K in Q4 2016. 49 funds tracked by Wall St. Rank hold NVLN as of Q3 2018.

  • Norges Bank reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q3 2018 after selling out during the quarter.
  • Norges Bank sold 39,700 Novelion Therapeutics Inc. Common Shares shares in Q3 2018, an estimated $146K.
  • Norges Bank first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 7 quarters.
  • Norges Bank's Novelion Therapeutics Inc. Common Shares position peaked at $594K in Q4 2016.
  • 49 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2018.

Based on Norges Bank's 13F filing for Q3 2018, filed 9 Nov 2018.